The Ozempic Hype, Insatiable, and What the Pens Can and Can't Do

Why a fictional story is suddenly about real pens

The Ozempic hype has picked up an unlikely sidekick: a Netflix show that most people watched for the drama. Insatiable premiered on Netflix in 2018 and was created by Lauren Gussis. It follows Patty, a teenager bullied over her weight. After a brutal beating leaves her jaw wired shut, she drops pounds fast. She then turns to beauty pageants and a revenge plot against the people who tormented her. It's best described as a dark comedy-drama, and many viewers read it as a commentary on weight and worth.

The link to injectable drugs came mostly from viewers. The show premiered years before Wegovy won US approval in 2021, and we couldn't find a creator interview that ties the story to GLP-1 pens. So treat the connection as the audience's idea, not the writers' intent. Once people started posting side-by-side clips and jokes about 'Ozempic thinness', the comparison took on a life of its own.

The thinness narrative and the before and after trap

Social media loves a dramatic transformation. One before-and-after photo can travel much further than a careful explanation of what a study measured. That shapes expectations. Many people now picture a fast, dramatic change as the normal result of an injection.

The trial numbers tell a more measured story. In the STEP 1 trial, published in the New England Journal of Medicine in 2021 by Wilding and colleagues, people taking semaglutide 2.4 mg lost roughly 15% of their body weight on average at 68 weeks. The placebo group lost roughly 2%. The SURMOUNT-1 trial of tirzepatide, published in NEJM in 2022 by Jastreboff and colleagues, reported average losses of about 21% at the highest dose at 72 weeks, compared with about 3% on placebo.

Those are averages across a group. Some participants lost much more, some lost less, and results depend on the person and on sticking with treatment. Influencer posts rarely show the boring parts: the dosing schedule, the people who stopped early, or what happened after the last dose. Many trials run for a fixed period, so what happens once someone stops is a separate question worth raising with a prescriber. Comparing your body to a filtered photo can also leave people feeling worse about their own bodies, whatever they're taking or not taking.

The hype in numbers and market reality

Sales of semaglutide and tirzepatide have climbed quickly, and both Novo Nordisk and Eli Lilly report their figures in quarterly earnings releases. If you want exact numbers, check the investor pages for each company and note the quarter. A headline percentage without a date tells you very little. Rising sales show demand, not proof that every user gets the same benefit.

Demand also collided with supply. The FDA listed semaglutide and tirzepatide on its drug shortage database during supply problems. That gap pushed some people toward compounded or unapproved products sold online or through telehealth. The FDA has issued public warnings about compounded and unapproved versions of both drugs. Read those notices directly for their exact dates, and check the shortage database for the current status, since listings change.

A spike in search volume or social posts only tells you people are talking. It doesn't prove clinical benefit, and it doesn't tell you a product is safe. Treat a trending pen the way you'd treat any trending product: interesting signal, weak evidence.

What these drugs are actually approved to do

Ozempic (semaglutide) was approved by the FDA in December 2017 for type 2 diabetes. Wegovy, which uses semaglutide at 2.4 mg, was approved by the FDA in 2021 for chronic weight management. The two share an active ingredient, but they are different products with different labels. So the answer to 'are Ozempic and Wegovy the same thing?' is: same molecule, different approved uses and doses.

The labels describe the mechanism in plain terms. GLP-1 receptor activity affects appetite signaling in the brain, and it slows gastric emptying, which means food leaves the stomach more slowly. That's why many people feel full sooner or for longer. The science is still being studied, so don't read more into it than the label says.

Approved indications differ by product and by country. In Brazil, check the labels on the ANVISA website at gov.br/anvisa. In Europe, the EMA publishes product information for each authorized medicine. Off-label use is a clinical decision, not a shortcut. When you check a label, look at the indication, the dose, and the warnings. For ongoing coverage of these labels and approvals, the OzemNews team publishes updates at https://ozemnews.com.

The risks the show and the hype leave out

The most common side effects in the labels are gastrointestinal. Expect possible nausea, vomiting, diarrhea, and constipation. Most people who experience them report they ease over time, but they can still be unpleasant, and they can lead to dehydration if they're severe.

The labels also carry serious warnings. Pancreatitis and gallbladder problems are listed. The label includes a boxed warning about thyroid C-cell tumors, based on rodent studies. The drug should not be used by people with a personal or family history of medullary thyroid carcinoma, or by people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Read the current prescribing information in Drugs@FDA for the exact wording, because labels get updated.

Buying from unverified online sellers adds a risk the show never touches. Compounded doses with no traceable origin may not contain what the seller claims, and the FDA has warned consumers about exactly this problem. Our running coverage of safety alerts tracks these notices as they come out. A clinician who knows your history can weigh a drug's risks against your conditions and medications, and that review matters far more than any online comparison. No injectable is risk-free.

Separating curiosity from a plan

If you're thinking about starting, a short list of questions helps. Ask why this drug fits your situation, what goal you and your prescriber are aiming for, what monitoring will look like, and what to do if side effects show up. A good answer should feel specific, not vague.

Set realistic expectations. These drugs can help many people with weight and blood sugar, but results vary, they are not a cure, and maintenance often matters as much as the first few months. Lifestyle factors can shape results too. Sleep, adequate protein, and strength training may help preserve muscle while weight changes, though the exact effect differs from person to person.

The show is entertainment, and the pen is medicine. The public conversation sits somewhere between the two, and that's where most of the confusion comes from. Stay curious, check the labels, and let the people treating you do the deciding. The OzemNews team keeps tracking the research and the regulatory updates, so stay tuned to OzemNews when the next wave of headlines hits.

FAQ

Is Insatiable a horror show about Ozempic?

No. Insatiable is a Netflix dark comedy-drama from 2018, created by Lauren Gussis. It isn't about GLP-1 drugs. Viewers made the connection themselves.

Are Ozempic and Wegovy the same thing?

They contain the same active ingredient, semaglutide, but they are approved for different uses and doses. Always check the label for the specific product you're considering.

Can GLP-1 pens help with appetite?

The labels describe GLP-1 receptor activity affecting appetite signaling and slowing gastric emptying. For many people this may help them feel full sooner, but responses vary.

Is compounded semaglutide safe?

The FDA has warned consumers about compounded and unapproved versions of these drugs. Quality and dosing can be uncertain, so talk with a clinician before considering any compounded product.

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022
• FDA Drug Shortages
• FDA Drugs@FDA Database
• ANVISA, Agência Nacional de Vigilância Sanitária
• European Medicines Agency